Markets

Insider Trading

Hedge Funds

Retirement

Opinion

20 Countries with the Highest Heart Disease Deaths Per Capita

In this article, we will be taking a look at the 20 countries with the highest disease deaths per capita. If you do not want to learn about the global heart disease landscape, head straight to the 5 Countries with the Highest Heart Disease Deaths Per Capita.

Global and US Heart Disease Landscape 

Cardiovascular diseases (CVDs) represent a significant global health concern, claiming an estimated 17.9 million lives annually due to heart-related conditions. The burden of heart disease is substantial, affecting individuals worldwide and leading to premature deaths, primarily caused by heart attacks and strokes. In 2020, approximately 19.1 million deaths were attributed to CVD globally, with an age-adjusted death rate of 239.8 per 100,000 population. Ischemic heart disease remains the leading cause of global CVD mortality, with an age-standardized rate of 108.8 per 100,000. The prevalence of stroke in 2020 was reported at 89.1 million people globally. 

The United States faces a significant burden of heart disease, with a considerable number of individuals affected by various cardiovascular conditions. Detailed statistics indicate that in the US, approximately 244.1 million people were living with ischemic heart disease in 2020, with higher prevalence rates in males than females. The age-standardized mortality rates for ischemic heart disease were reported at 112.37 per 100,000 population in the same year. 

The economic impact of heart disease is substantial globally and in the US. In the US market specifically, the financial implications of managing heart diseases are significant, encompassing costs related to treatment, medication, surgeries, and overall healthcare expenditure. Access to essential technologies and medications for cardiovascular conditions is crucial in the US healthcare system to ensure prompt management of acute events like heart attacks and strokes. 

Revolutionizing Cardiovascular Health: Innovations, Insurance, and Economics 

The global cardiovascular health landscape is marked by its complexity, with cardiovascular diseases (CVDs) posing a formidable challenge. This necessitates innovative solutions for treatment and management. Both the pharmaceutical and medical device sectors have made significant strides in addressing this challenge. Specifically, pharmaceutical innovations, including gene therapies and RNA-based therapeutics, have reshaped the treatment paradigm. Notable examples include Eliquis (apixaban) by Bristol-Myers Squibb Company (NYSE:BMY), demonstrating superior risk reduction capabilities. 

Bristol-Myers Squibb Company (NYSE:BMY) is renowned for its pioneering work in cardiovascular disease (CVD) treatments, focusing on preventing strokes, treating venous thromboembolism, and addressing conditions like Hypertrophic Cardiomyopathy (HCM). Their recent approval of CAMZYOS (mavacamten) as a cardiac myosin inhibitor for obstructive HCM signifies a significant breakthrough, showing efficacy in improving exercise capacity and symptoms. Looking forward, Bristol-Myers Squibb Company (NYSE:BMY) aims to lead in personalized medicine and precision therapies, leveraging innovative research and development. Financially, the company saw a 1% increase in revenues to $11.5 billion in the fourth quarter of 2023, with strong performance from key products like Eliquis and Opdivo. Adjusted EPS decreased by 7% to $1.70 for the same period, and for the full year of 2024, the company expects revenues to increase by low single-digits with adjusted EPS ranging between $7.10-7.40. 

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) employs a groundbreaking Gene Therapy platform, utilizing adeno-associated viruses (AAVs) to address root causes of heart diseases such as hypertrophic cardiomyopathy (HCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC) with leading treatments like TN-201 and TN-401. Their Cellular Regeneration platform aims to restore heart function post-myocardial infarction by regenerating cardiomyocytes in vivo. Leveraging Precision Medicine with hiPSC-CMs, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) develops tailored treatments for genetic and non-genetic heart diseases. Noteworthy trends include HDAC6 inhibitors for heart failure with preserved ejection fraction (HFpEF) and gene replacement therapies. Financially, Tenaya Therapeutics, Inc. (NASDAQ:TNYA) reported a net loss of $29.9 million for Q4 and $124.1 million for the full-year 2023, emphasizing ongoing investment in genetic medicines for heart disease. Notably, TN-201 for HCM and TN-401 for ARVC are advancing in clinical trials, while TN-301 shows promising data for HFpEF. With $104.6 million in cash and recent financing, Tenaya is well-positioned for future growth. 

Medical devices, including implantable cardioverter-defibrillators (ICDs), pacemakers, and stents, play a crucial role in managing cardiovascular conditions, complementing pharmaceutical treatments. Integration of digital health technologies enhances patient care through real-time monitoring and personalized interventions. The global digital health market, valued at $96.5 billion in 2020, is projected to grow at a CAGR of 15.1% from 2021 to 2028. 

Amidst these advancements, health insurance trends play a pivotal role in ensuring access to quality cardiovascular care. Insurers are adapting to provide comprehensive coverage encompassing medications, medical devices, diagnostics, and procedures, aligning with the growing demand for accessible healthcare solutions. 

Our Methodology 

Our methodology for ranking countries with the highest heart disease deaths per capita involved calculating death rates per capita based on total deaths per capita due to heart diseases. The data we used was heart disease death rates per 100,000 individuals, we initially divided the death rate per 100,000 by 100,000. Then, we multiplied this result by each country’s total population and subsequently divided by total population to derive death rates per capita. These figures were then arranged in ascending order to determine the countries with the highest heart disease deaths per capita. 

Here is our list of the 20 countries with the highest heart disease deaths per capita.

20. Sudan 

Death Rate per Capita: 0.002 

In Sudan, heart disease presents a significant health challenge, encompassing various conditions such as hypertensive heart disease, rheumatic heart disease, ischemic heart disease, and cardiomyopathy, which collectively account for over 80% of cardiovascular diseases. Hypertension prevalence stands at around 20%, totaling 74,371 deaths. Heart diseases affect individuals across different age groups, including children, with conditions like rheumatic heart disease impacting them.  

19. Morocco 

Death Rate per Capita: 0.002 

Morocco faces significant challenges with cardiovascular diseases (CVD), particularly heart disease, as it ranks high in CVD-related mortality. The country’s healthcare system is strained, with a mortality rate of 38% attributed to CVD. Ischemic heart disease and stroke are the primary causes of death, accounting for 31.0% and 22.5%, respectively. Risk factors contributing to this high mortality rate include tobacco smoking (45-50%), physical inactivity (21.1%), hypertension (25.3%), and depression (5.47%).

18. Egypt 

Death Rate per Capita: 0.002

Egypt stands among the countries with the highest disease deaths per capita, with a high prevalence rate of coronary heart disease (CHD) at 5,623.95 per 100,000 individuals and a mortality rate of 359.3 per 100,000. While some individuals recover, there’s a notable mortality rate, highlighting the seriousness of the condition. Hospitalized heart failure patients in Egypt range from 52.2 to 62.8 years old, showing its impact across age groups. 

17. Yemen 

Death Rate per Capita: 0.002 

Yemen stands among the top countries with high rates of heart diseases. While some individuals recover, many succumb to the disease. Treating heart disease in Yemen poses a significant financial burden on individuals and the healthcare system, highlighting the importance of accessibility to affordable and quality healthcare services.  

16. Turkmenistan 

Death Rate per Capita: 0.002  

In Turkmenistan, coronary heart disease is responsible for 29.02% of total deaths. Raised blood pressure affects a notable portion of the population, with prevalence rates of 24.1% in women and 26.6% in men. Additionally, tobacco smoking prevalence is high at 12.5%, contributing significantly to cardiovascular disease incidence and mortality rates in Turkmenistan.

15. Syria 

Death Rate per Capita: 0.002

Syria faces a significant burden of coronary heart disease (CHD) mortality. The prevalence of cardiovascular disease (CVD) is notable, with 4.8% of adults in Aleppo suffering from heart disease and 1.0% from stroke. CVD accounts for 45.0% of total mortality, with 49% of deaths occurring before age 65. The mean age of death due to CVD is approximately 62.6 years. Modern treatments have prevented about one-fourth of total CHD mortality in Syria.

14. Micronesia 

Death Rate per Capita: 0.002 

Micronesia faces coronary heart disease issues accounting for nearly 18.8% of total deaths. Raised blood pressure affects over 23% of women and 26% of men, while tobacco smoking prevalence stands at 49.4%. The country has implemented most key cardiovascular disease policies and has a national action plan in place.

13. Belarus 

Death Rate per Capita: 0.002 

Micronesia has high Coronary Heart Disease (CHD) rates, constituting 19.88% of total deaths. Micronesia’s health expenditure accounts for 11% of its GDP, with a GDP per capita of US$3,629 in 2019.

12. Mongolia 

Death Rate per Capita: 0.002 

Mongolia faces significant challenges with heart disease, notably Ischaemic Heart Disease (IHD), affecting around 14% of individuals aged 15-69. Hemorrhagic stroke incidence is notably higher in Mongolia compared to global rates. Mortality rates for stroke are severe, with over two-thirds leading to death or disability within a year, and one-third resulting in death within 28 days. Initiatives like ‘MongPEN’ aim to address heart health, but limited resources hinder improvements. The government aims to reduce CVD mortality as part of its Sustainable Development Vision 2030, but challenges in policy implementation and industry engagement remain. 

11. Vanuatu 

Death Rate per Capita: 0.002 

Vanuatu stands among the countries with the highest disease deaths per capita. Heart disease prevalence contributes substantially to overall mortality, with ischemic heart disease and stroke being major concerns. Both genders are affected, with adults aged 15-59 bearing a significant burden of cardiovascular diseases like heart attacks and diabetes. 

10. Moldova 

Death Rate per Capita: 0.0024 

In 2019, Moldova experienced a significant burden of heart disease, with 23,438 deaths attributed to cardiovascular disease. Raised blood pressure affected 26.2% of women and 33.6% of men, while tobacco smoking prevalence was at 23.6%. Circulatory system diseases accounted for 51% of total deaths, with notable rates for conditions like coronary heart disease (314.9 per 100,000) and stroke (159.2 per 100,000).   

9. Kiribati 

Death Rate per Capita: 0.0024 

Kiribati stands among the countries with the highest disease deaths per capita, evidenced by high rates of raised blood pressure (19.0% in women, 24.0% in men) and tobacco smoking prevalence (48.7% among individuals aged 15 and older). The country recorded 2,792 deaths from cardiovascular disease in 2019. Urgent action is needed to implement effective prevention and treatment strategies to improve heart health outcomes in Kiribati.  

8. Kyrgyzstan 

Death Rate per Capita: 0.0024 

Kyrgyzstan grapples with a significant burden of cardiovascular diseases (CVD), notably coronary heart disease, which accounts for 32.35% of total deaths, ranking 16th globally. CVD mortality rates have risen over the years, with half of all deaths attributed to CVD in 2011, claiming over 18,000 lives annually. Economic losses from CVD in 2007 were estimated at over 14 billion soms (around 360 million US Dollars), underscoring the need for healthcare system restructuring to address this health crisis comprehensively. 

7. Solomon Island 

Death Rate per Capita: 0.0028 

In the Solomon Islands, heart disease is the leading cause of death, with cardiovascular diseases claiming numerous lives annually. The National Referral Hospital sees a significant percentage of admissions for heart-related issues, with heart failure alone accounting for 23% of deaths. The GDP per capita was US$2,344 in 2019, with health expenditure accounting for 5% of GDP.  

6. Afghanistan 

Death Rate per Capita: 0.003 

Afghanistan faces high coronary heart disease (CHD) rates, with nearly one in ten adults affected. Factors contributing to this include older age, tobacco use, high cholesterol levels, and inadequate fruit and vegetable consumption. The prevalence of ideal cardiovascular health (ICVH) is low, with over one-third having 5-7 ICVH, 45.7% having 3-4 ICVH, and 20% having 0-2 ICVH.  

 Click to see an continue reading the 5 Countries with the Highest Disease Deaths per Capita.

Suggested Articles:

Disclosure. None: The 20 countries with the highest disease deaths per capita is originally published on Insider Monkey. 

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 75%.

For a ridiculously low price of just $24, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

  • The Name of the Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.
  • Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.
  • Lifetime Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund ANYTIME, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

  1. Head over to our website and subscribe to our Premium Readership Newsletter for just $24.
  2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.
  3. Sit back, relax, and know that you’re backed by our ironclad lifetime money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!

Subscribe Now!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…